康复新液辅助抗结核药治疗肠结核的疗效及对血清、肠黏膜血管内皮生长因子和核因子κB的影响  

Efficacy of Kangfuxin Liquid Combined with Anti-Tuberculosis Drugs in the Treatment of Intestinal Tuberculosis and Effects on Levels of Vascular Endothelial Growth Factor and Nuclear Factor-κB in Serum and Intestinal Mucosa

作　　者：魏书青 高金昙[1] 陈庆[1] 张敏[1] 刘培乾 马静 赵伟进 WEI Shuqing;GAO Jintan;CHEN Qing;ZHANG Min;LIU Peiqian;MA Jing;ZHAO Weijin(Dept.of Gastroenterology,Hebei Chest Hospital,Shijiazhuang 050041,China;Dept.of Geriatrics,People’s Hospital of Wei County,Hebei Xingtai 054700,China;Dept.of Pharmacy,Shijiazhuang City Luancheng People’s Hospital,Shijiazhuang 051430,China)

机构地区：[1]河北省胸科医院消化内科,石家庄050041 [2]河北省威县人民医院老年病科,河北邢台054700 [3]石家庄市栾城人民医院药剂科,石家庄051430

出　　处：《中国医院用药评价与分析》2022年第2期165-168,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：河北省中医药管理局科研计划项目(No.2021117)。

摘　　要：目的:探讨康复新液辅助抗结核药治疗肠结核的疗效及对血清、肠黏膜血管内皮生长因子(VEGF)和核因子κB(NF-κB)的影响。方法:选取2019年9月至2021年1月河北省胸科医院收治的60例肠结核患者,按照随机数字表法分为常规组和联合组,每组30例。常规组患者采用抗结核药治疗,联合组患者在常规组的基础上加用康复新液辅助治疗。观察两组患者的治疗疗效、症状改善时间,治疗前后血清和肠黏膜相关指标水平,肝损伤和不良反应发生情况。结果:联合组患者治疗总有效率为93.33%(28/30),显著高于常规组的73.33%(22/30),差异有统计学意义(P<0.05)。联合组患者症状改善时间显著短于常规组,差异有统计学意义(P<0.05)。两组患者治疗后的血清指标VEGF、NF-κB、肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)和C反应蛋白(CRP),肠黏膜组织VEGF、NF-κB和蛋白激酶(PAK)水平较治疗前显著改善;联合组患者治疗后的血清VEGF水平显著高于常规组,NF-κB、TNF-α、IL-1β和CRP水平显著低于常规组;肠黏膜组织VEGF水平显著高于常规组,NF-κB、PAK水平显著低于常规组,上述差异均有统计学意义(P<0.05)。联合组、常规组患者肝功能损伤发生率[23.33%(7/30)、30.00%(9/30)]和不良反应发生率[16.67%(5/30)、23.33%(7/30)]比较,差异均无统计学意义(P>0.05)。结论:采用康复新液辅助抗结核药治疗肠结核的疗效显著,其作用机制可能为康复新液通过抑制NF-κB表达、上调VEGF表达而抑制炎症反应,促进黏膜修复,进而改善患者相关症状,提高治疗效果。OBJECTIVE: To explore the efficacy of Kangfuxin liquid combined with anti-tuberculosis drugs in the treatment of intestinal tuberculosis and effects on levels of vascular endothelial growth factor(VEGF) and nuclear factor-κB(NF-κB) in serum and intestinal mucosa. METHODS: Totally 60 patients with intestinal tuberculosis admitted into Hebei Chest Hospital from Sept. 2019 to Jan. 2021 were extracted to be divided into the routine group and combined group via the random number table, with 30 cases in each group. The routine group was treated with anti-tuberculosis drugs, while the combined group were additionally given Kangfuxin liquid based on the routine group. The efficacy, symptom improvement time, serum and intestinal mucosa related indicators before and after treatment, liver function injury and adverse drug reactions in two groups were observed. RESULTS: The total effective rate of the combined group was 93.33%(28/30), significantly higher than that of the routine group 73.33%(22/30), the difference was statistically significant(P<0.05). Symptom improvement time in the combined group was significantly shorter than that in the routine group, the difference was statistically significant(P<0.05). After treatment, the VEGF, NF-κB, tumor necrosis factor alpha(TNF-α), interleukin-1β(IL-1β) and C-reactive protein(CRP) in serum, and VEGF, NF-κB and protein kinase(PAK) in intestinal mucosa in two groups were significantly improved. After treatment, the levels of VEGF in serum in the combined group were significantly higher than those in the routine group, the levels of NF-κB, TNF-α, IL-1β and CRP in serum in the combined group were significantly lower than those in the routine group;the levels of VEGF in intestinal mucosa in the combined group were significantly higher than those in the routine group, the levels of NF-κB and PAK in intestinal mucosa were significantly lower than those in the routine group, with statistically significant difference(P<0.05). There were no significant differences in the incide

关 键 词：康复新液 抗结核药 肠结核 疗效 肠黏膜 血管内皮生长因子 核因子ΚB 

分 类 号：R978.3[医药卫生—药品] R932[医药卫生—药学]